Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Filippo PietrantonioRiccardo LobefaroMaria AntistaSara LonardiAlessandra RaimondiFederica MoranoStefania MosconiLorenza RimassaSabina MurgioniAndrea Sartore-BianchiGianluca TomaselloRaffaella LongariniGabriella FarinaFausto PetrelliStefania GoriGiovanni RandonSalvatore CoralloFilippo PaganiVincenzo GuariniFederica PalermoAntonia MartinettiMarco MacagnoLudovic BaraultFederica PerroneElena TamboriniMassimo MilioneFederica Di NicolantonioMassimo Di MaioGiovanni FucàMaria Di BartolomeoFilippo de BraudPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Temozolomide-based therapy warrants further investigation in molecularly hyperselected subgroups.